CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 65 enrolled
Drug / intervention
intranasal povidone-iodinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04146116
NCT04146116Phase 4Completed
CompareCT.gov

Feasibility of Pre-operative Povidone Iodine Decolonization Among Orthopedic Trauma Surgery Patients To Reduce Staphylococcus Aureus Surgical Site Infections

University of Iowa·interventional·Posted Oct 31, 2019·Updated Jun 28, 2023

In Brief

A Phase 4 clinical trial evaluating intranasal povidone-iodine for Surgical Site Infection. Completed, enrolled 65 participants across 1 site.

Detailed Summary

Many surgical site infections are caused by bacteria that is transferred from a patient's nose to their open surgical wound. Some small studies have shown that putting povidone-iodine in a patient's nose reduces this risk. This study aims to evaluate the real-world effectiveness of nasal povidone-iodine (PROFEND®) in a group of 50 patients at the University of Iowa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSurgical Site Infection
CountriesUnited States
CollaboratorsProfessional Disposables International, Inc.

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedOct 31, 2019
Enrollment StartFeb 19, 2020
Primary CompletionJun 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.7 years ago

Interventions

intranasal povidone-iodinedrug

povidone-iodine USP, 10% w/w antiseptic